Clinical trials
Patient clinical trials
Below are recruiting patient clinical trials, each written for real people, not researchers. We’re tracking 14,187 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06510972Recruiting
Eating versus fasting for ICU patients with breathing failure
This study looks at whether it's safe and helpful to let people with severe breathing problems in the ICU eat and drink normally instead of fasting. If you qualify, you may be assigned to either continue eating or to fast while doctors monitor your recovery.
BloisAges 18 years+ - NCT06511882RecruitingPhase 2
Stopping AML treatment after reaching remission with no detectable disease
This trial tests whether it is safe to stop taking a type of chemotherapy (azacitidine or decitabine) combined with venetoclax if you have acute myeloid leukemia (AML) and have achieved a remission with no trace of leukemia cells. If you have been on this treatment for less than a year and are not eligible for a stem cell transplant, you may be able to stop therapy and be monitored closely.
Tampa, FloridaAges 18 years+ - NCT06511401Recruiting
Pain treatment guided by your genes
This study looks at whether knowing your genetic makeup can help doctors choose the safest and most effective pain medicine for you before you start taking opioids. If you are being treated for cancer and may need opioid pain medication soon, this trial might be a fit.
Chicago, IllinoisAges 18 years+ - NCT06512662Recruiting
Support program for ENT cancer patients in a day hospital
This trial offers a support program for patients undergoing surgery for head and neck cancer. The goal is to help with recovery and well-being.
BrestAges 18 years+ - NCT06504485Recruiting
Study of bulevirtide for chronic hepatitis B and D
This trial tests a drug called bulevirtide for people with chronic hepatitis B and D (HDV) co-infection. It looks at how the immune system and virus respond to treatment.
MilanAges 18 years+ - NCT06507150Recruiting
AI-assisted migraine education for newly diagnosed patients
This study tests a new AI-powered learning tool to help people who were just diagnosed with migraine understand their condition better. You'll use the tool on your own device, and researchers will see if it's helpful and easy to use.
LuganoAges 18–65 - NCT06510868Recruiting
MDS risk study for NET patients before or after PRRT
This study looks at the risk of developing Myelodysplastic Syndrome (MDS), a blood disorder, in people with Neuroendocrine Tumors (NET) who are treated with Peptide Radionuclide Therapy (PRRT). It involves a simple blood test to check for genetic changes linked to MDS. Participating can help understand and potentially prevent this side effect.
Toronto, OntarioAges Any age - NCT06498973RecruitingPhase 1
Maintenance therapy after stem cell transplant for CD123-positive AML/MDS
This trial tests a combination of two drugs, tagraxofusp and azacitidine, given as maintenance therapy after a stem cell transplant. The goal is to prevent the leukemia or MDS from coming back in patients whose cancer cells carry a specific marker called CD123.
Duarte, CaliforniaAges 18–75 - NCT06511518Recruiting
Talking therapy for fatigue in advanced cancer
This study tests whether cognitive behavioral therapy, a type of talking therapy, can help reduce severe fatigue in people with advanced solid tumors or gliomas who are receiving or have completed palliative treatment. The goal is to see if this approach improves energy levels and quality of life.
Amsterdam, North HollandAges 18 years+ - NCT06502275Recruiting
Nutrition and Exercise for Older Colorectal Cancer Patients
This trial tests a nutrition and exercise program designed for older adults with colorectal cancer. It uses a smartphone app to help you stay active and eat well at home.
Chiayi CityAges 60 years+ - NCT06498154RecruitingPhase 2
Skipping breast surgery for some patients after chemo
This trial tests whether women with certain aggressive breast cancers (HER2-positive without hormone receptors, or triple-negative) can safely skip breast surgery if chemotherapy makes their tumor completely disappear. The goal is to avoid surgery and its side effects when it may no longer be needed.
TianjinAges 18–70 - NCT06510361RecruitingPhase 2
Epcoritamab for follicular lymphoma not cured by initial treatment
This trial tests a drug called epcoritamab for people with follicular lymphoma (a type of slow-growing blood cancer) that improved but did not completely go away after standard first therapy. The goal is to see if epcoritamab can help achieve a complete remission.
Stanford, CaliforniaAges 18 years+ - NCT06511648RecruitingPhase 2
Erdafitinib with or without immunotherapy for FGFR-altered bladder cancer
This trial tests a targeted therapy called erdafitinib, either alone or combined with an immunotherapy drug (cetrelimab), for people with muscle-invasive bladder cancer that has a specific FGFR gene change. It may be an option if you cannot take cisplatin chemotherapy and have not had prior treatment for this cancer.
Clermont-FerrandAges 18 years+ - NCT06500156Recruiting
Metabolic patterns in septic shock patients
This study looks at how the body uses energy (metabolism) in people with septic shock. It collects information from standard monitoring during a fluid challenge (a small IV fluid test) to find patterns that might help doctors better understand and treat septic shock.
Sabadell, BarcelonaAges 18 years+ - NCT06513156Recruiting
Care support for hospitalized patients with drug-related infections
This study is for people who are in the hospital with a serious infection caused by injection drug use. It aims to provide better care and support while you are in the hospital and after you leave.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06496035Recruiting
Blood flow training for leg fracture recovery
This study tests whether a special exercise method called blood flow restriction training helps people heal faster after a broken shinbone (tibia). It might improve strength and recovery during physical therapy.
Denver, ColoradoAges 18–100 - NCT06502691RecruitingPhase 1/Phase 2
New imaging test to measure PARP in metastatic breast cancer
This trial tests a new imaging scan called [18F]FTT PET that may show how much of a protein called PARP is in your tumors. This could help doctors decide if a PARP inhibitor (a type of targeted therapy) is right for you. You may be able to join if you have metastatic breast cancer and are already planning to take a PARP inhibitor.
Seattle, WashingtonAges 18 years+ - NCT06497530RecruitingPhase 2
Lurbinectedin with serplulimab for extensive-stage SCLC maintenance
This trial tests a combination of two drugs, lurbinectedin and serplulimab, as maintenance therapy after initial chemotherapy for people with extensive-stage small cell lung cancer (SCLC) that hasn't spread to the brain. The goal is to see if this approach helps keep the cancer from growing for longer.
Guangzhou, GuangdongAges 18 years+ - NCT06496295Enrolling by invitation
Testing a new speculum for cervical cancer screening
This trial tests a new kind of vaginal speculum (the tool used to look inside the vagina during a pelvic exam). It is for people who have never had this exam before, to see if it works well for cervical cancer screening.
Englewood, ColoradoAges 18–65 - NCT04150497RecruitingPhase 1/Phase 2
Testing a new cell therapy for CD22-positive leukemia
This trial tests UCART22, a new cell-based treatment, for people with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) that has the CD22 marker. It may help by attacking leukemia cells that carry CD22.
Los Angeles, CaliforniaAges 15–50 - NCT04893564Recruiting
Testing blood DNA after 6 months of Waldenström treatment
This study looks at a blood test called circulating tumor DNA, measured after 6 months of treatment, to see how well it predicts outcomes in people with Waldenström macroglobulinemia. It may help doctors better judge who is responding and who may need treatment adjustments earlier.
AmiensAges 18 years+ - NCT06480383RecruitingPhase 2
Adding an experimental pill to current anxiety medication
This study tests an experimental medication (ITI-1284) added to your current anxiety treatment to see if it improves symptoms. It's for adults with generalized anxiety disorder (GAD) who haven't gotten enough relief from their current medicine.
Glendale, CaliforniaAges Any age - NCT06492720Recruiting
Testing focused ultrasound for drug-resistant epilepsy
This study tests a new device called NaviFUS that uses focused sound waves to gently stimulate a small area of the brain. It is for people whose seizures start in one part of the brain and are not fully controlled by seizure medicines.
TaipeiAges 18–65 - NCT06478719RecruitingPhase 1/Phase 2
FB-1603 plus TACE for liver cancer patients
This trial tests a new medicine (FB-1603) given along with standard TACE procedure for people with liver cancer. It aims to see if the combination is safe and works better than TACE alone.
Taipei, TaiwanAges 18–85
Hear when a new Patient trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for patient?
- Yes. Clin2 currently lists 14,187 recruiting patient studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a patient trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a patient trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.